Spots Global Cancer Trial Database for Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Official Title: Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Study ID: NCT00237211
Interventions
Study Description
Brief Summary: To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Matsuyama, Ehime, Japan
Novartis Investigative Site, Kooriyama, Fukushima, Japan
Novartis Investigative Site, Maebashi, Gunma, Japan
Novartis Investigative Site, Kurashiki, Okayama, Japan
Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan
Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site, Chuo-ku, Tokyo, Japan
Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan
Novartis Investigative Site, Fukushima, , Japan
Novartis Investigative Site, Osaka, , Japan
Novartis Investigative Site, Saitama, , Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
